Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

On Thursday, shares of Ebix, Inc. (NASDAQ: EBIX) experienced volatile short activity. After the activity, the stock price went down -37.65% to $14.59. The overall sentiment for EBIX has been Neutral.

Benzinga

Short Volatility Alert: Legend Biotech Corporation

On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went down -1.38% to $42.96. The overall sentiment for LEGN has been Bullish.

Benzinga

Short Volatility Alert: Strategic Education, Inc.

On Thursday, shares of Strategic Education, Inc. (NASDAQ: STRA) experienced volatile short activity. After the activity, the stock price went down -2.77% to $60.00. The overall sentiment for STRA has been Neutral.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pactiv Evergreen Introduces Tamper Evident Fry Cartons

Pactiv Evergreen Inc (NASDAQ:PTVE) has launched new Tamper Evident Fry Cartons to meet the evolving needs of foodservice operators. Tamper Evident Fry Cartons were designed with portability, safety, and security in mind to cater to the takeout and delivery market. It has a tamper-evident latch that must be torn to access the contents…

Benzinga

Why Scholar Rock Shares Are Trading Higher Today

Scholar Rock Holding Corp (NASDAQ:SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) receiving an SMN therapy. The trial assessed patient outcomes after 24 months of treatment. All 35 non-ambulatory patients (Cohorts 2 and 3) and…

Benzinga

Merck Shows Takeover Interest In Seagen: WSJ

Merck & Co Inc (NYSE:MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion. According to the report, some people said other unnamed suitors are also eying Seagen, a…

Benzinga

5 Analysts Have This to Say About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals (NASDAQ:RYTM) has observed the following analyst ratings within the last quarter:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings for Grab Hldgs

Analysts have provided the following ratings for Grab Hldgs (NASDAQ:GRAB) within the last quarter:

Benzinga

WISeKey Forges NFT Collaboration With The China Museum Of Finance

Cybersecurity, AI, Blockchain, and IoT company WISeKey International Holding AG (NASDAQ:WKEY) collaborated with The China Museum of Finance to offer Trusted NFTs with the launch of WISe.ART NFT platform. The WISe.ART NFT Platform is an Ethereum scaling and infrastructure development available with Ethereum-compatible blockchains. The WISe.ART platform will auction a historical NFT of the…

Benzinga

Emmy Awards Producers Approach Chris Rock And Dwayne Johnson For Hosting Duties: Report

An effort is underway to attract Chris Rock and/or Dwayne Johnson as potential hosts of the 74th Primetime Emmy Awards, which will be broadcast on Sept. 12 on NBC, a division of Comcast Corporation (NASDAQ: CMCSA).

Benzinga

Ominous Death Cross Forms On Keurig Dr Pepper's Chart

If history is any guide, there may be trouble ahead for shares of Keurig Dr Pepper (NASDAQ:KDP). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Ominous Death Cross Forms On Costco Wholesale's Chart

If history is any guide, there may be trouble ahead for shares of Costco Wholesale (NASDAQ:COST). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Here's Why Needham Sees Apple's Brand Value Worth At $1T

Needham analyst Laura Martin believes lifetime value (LTV) is the primary driver of upside value for Apple Inc (NASDAQ: AAPL) and that brand value is a leading indicator of LTV in a note titled "AAPL's Brand is Worth $1 Trillion."

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Looking At Advanced Micro Devices's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Advanced Micro Devices (NASDAQ:AMD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 17, 2022

Upgrades

Benzinga

Here's How Much $1000 Invested In Tesla 10 Years Ago Would Be Worth Today

Tesla (NASDAQ:TSLA) has outperformed the market over the past 10 years by 48.14% on an annualized basis producing an average annual return of 58.9%. Currently, Tesla has a market capitalization of $683.52 billion.

Benzinga

$1000 Invested In T-Mobile US 5 Years Ago Would Be Worth This Much Today

T-Mobile US (NASDAQ:TMUS) has outperformed the market over the past 5 years by 6.27% on an annualized basis producing an average annual return of 14.94%. Currently, T-Mobile US has a market capitalization of $160.94 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

How Is The Market Feeling About Lululemon Athletica?

Lululemon Athletica's (NASDAQ:LULU) short percent of float has fallen 5.64% since its last report. The company recently reported that it has 2.79 million shares sold short, which is 2.51% of all regular shares that are available for trading.

Benzinga

HTG Molecular Diagnostics's Return On Capital Employed Insights

HTG Molecular Diagnostics (NASDAQ:HTGM) brought in sales totaling $1.18 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 25.16%, resulting in a loss of $6.50 million.

Benzinga

NeuroPace Earnings Perspective: Return On Capital Employed

Benzinga Pro data, NeuroPace (NASDAQ:NPCE) reported Q1 sales of $11.37 million. Earnings fell to a loss of $11.46 million, resulting in a 7.18% decrease from last quarter.

Benzinga

Acutus Medical's Return On Capital Employed Overview

Benzinga Pro data, Acutus Medical (NASDAQ:AFIB) reported Q1 sales of $3.68 million. Earnings fell to a loss of $40.02 million, resulting in a 28.0% decrease from last quarter.

Benzinga

CASI Pharmaceuticals's Return On Capital Employed Insights

Benzinga Pro data, CASI Pharmaceuticals (NASDAQ:CASI) reported Q1 sales of $9.06 million. Earnings fell to a loss of $8.40 million, resulting in a 55.7% decrease from last quarter.

Benzinga

Aptevo Therapeutics's Return On Capital Employed Overview

Benzinga Pro data, Aptevo Therapeutics (NASDAQ:APVO) reported Q1 sales of $3.11 million. Earnings fell to a loss of $7.70 million, resulting in a 22.72% decrease from last quarter.

Benzinga

Cyxtera Technologies Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q1, Cyxtera Technologies (NASDAQ:CYXT) posted sales of $182.40 million. Earnings were up 37.65%, but Cyxtera Technologies still reported an overall loss of $40.90 million.

1 … 383 384 385 386

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.